董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert W. Postma | 男 | Director | 71 | 53.72万美元 | 未持股 | 2025-08-15 |
| Jaime Vieser | 男 | Director | 55 | 58.11万美元 | 未持股 | 2025-08-15 |
| Holger Weis | 男 | Director,Chair and Chief Executive Officer | 62 | 59.32万美元 | 未持股 | 2025-08-15 |
| Michael A. Jerman | -- | Director | -- | 未披露 | 未持股 | 2025-08-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ferdinand Groenewald | 男 | Vice President, Finance | 41 | 未披露 | 未持股 | 2025-08-15 |
| Holger Weis | 男 | Director,Chair and Chief Executive Officer | 62 | 59.32万美元 | 未持股 | 2025-08-15 |
董事简历
中英对照 | 中文 | 英文- Robert W. Postma
-
Robert W. Postma自2021年2月以来一直担任我们的董事会成员。Postma先生还曾担任WaterMill Asset Management Corp.的总裁，该公司于1999年7月创立。WaterMill使用Postma先生的资金积极交易市政债券和股票。Postma先生拥有超过44年的交易经验并获得了学士学位。拉斐特学院商业和经济学博士。
Robert W. Postma,has served as a member of Alaunos Therapeutics, Inc. Board since February 2021. Mr. Postma has also served as the president of WaterMill Asset Management Corp. ("WaterMill"), a company which he founded in July 1999. WaterMill actively trades in municipal bonds and equities, Alaunos Therapeutics, Inc. ing the funds of Mr. Postma. Mr. Postma has over 44 years of trading experience and received a B.A. in Business and Economics from Lafayette College. - Robert W. Postma自2021年2月以来一直担任我们的董事会成员。Postma先生还曾担任WaterMill Asset Management Corp.的总裁，该公司于1999年7月创立。WaterMill使用Postma先生的资金积极交易市政债券和股票。Postma先生拥有超过44年的交易经验并获得了学士学位。拉斐特学院商业和经济学博士。
- Robert W. Postma,has served as a member of Alaunos Therapeutics, Inc. Board since February 2021. Mr. Postma has also served as the president of WaterMill Asset Management Corp. ("WaterMill"), a company which he founded in July 1999. WaterMill actively trades in municipal bonds and equities, Alaunos Therapeutics, Inc. ing the funds of Mr. Postma. Mr. Postma has over 44 years of trading experience and received a B.A. in Business and Economics from Lafayette College.
- Jaime Vieser
-
Jaime Vieser自2020年12月以来一直担任我们的董事会成员。Vieser先生目前管理着一家私人投资公司Brushwood LLC。从2010年到2017年，他是Castle Hill Asset Management LLC的管理合伙人和联席负责人，这是一家价值27亿美元的资产管理公司和对冲基金，专注于高收益和不良债务。在创立Castle Hill之前，Vieser先生于1998年至2008年负责德意志银行在伦敦的高收益销售和交易集团。Vieser先生最初于1994年加入纽约的Bankers Trust，并在投资银行/杠杆融资部门工作。Vieser先生毕业于密歇根大学，获得经济学学位，毕业于南卫理公会大学考克斯商学院，获得工商管理硕士学位。
Jaime Vieser,has served as a member of Alaunos Therapeutics, Inc. Board since December 2020. Mr. Vieser currently manages Brushwood LLC, a private investment firm. From 2010-2017, he was a Managing Partner and co-principal of Castle Hill Asset Management LLC, a $2.7 billion asset manager and hedge fund focusing on high yield and distressed debt. Prior to founding Castle Hill, Mr. Vieser was responsible for Deutsche Bank's High Yield Sales and Trading Group in London from 1998 to 2008. Mr. Vieser originally joined Bankers Trust in New York in 1994 and worked in the Investment Banking/Leveraged Finance division. Mr. Vieser graduated from the University of Michigan with a degree in Economics and from the Cox School of Business at Southern Methodist University with a Master's in Business Administration. - Jaime Vieser自2020年12月以来一直担任我们的董事会成员。Vieser先生目前管理着一家私人投资公司Brushwood LLC。从2010年到2017年，他是Castle Hill Asset Management LLC的管理合伙人和联席负责人，这是一家价值27亿美元的资产管理公司和对冲基金，专注于高收益和不良债务。在创立Castle Hill之前，Vieser先生于1998年至2008年负责德意志银行在伦敦的高收益销售和交易集团。Vieser先生最初于1994年加入纽约的Bankers Trust，并在投资银行/杠杆融资部门工作。Vieser先生毕业于密歇根大学，获得经济学学位，毕业于南卫理公会大学考克斯商学院，获得工商管理硕士学位。
- Jaime Vieser,has served as a member of Alaunos Therapeutics, Inc. Board since December 2020. Mr. Vieser currently manages Brushwood LLC, a private investment firm. From 2010-2017, he was a Managing Partner and co-principal of Castle Hill Asset Management LLC, a $2.7 billion asset manager and hedge fund focusing on high yield and distressed debt. Prior to founding Castle Hill, Mr. Vieser was responsible for Deutsche Bank's High Yield Sales and Trading Group in London from 1998 to 2008. Mr. Vieser originally joined Bankers Trust in New York in 1994 and worked in the Investment Banking/Leveraged Finance division. Mr. Vieser graduated from the University of Michigan with a degree in Economics and from the Cox School of Business at Southern Methodist University with a Master's in Business Administration.
- Holger Weis
-
Holger Weis自2020年12月以来一直担任我们的董事会成员。自2018年4月成立以来，Weis先生继续担任Weis Advisors，Inc.的负责人，该公司为生命科学公司提供咨询服务。在此之前，他曾在DemeRx，Inc.担任过多个职务，DemeRx，Inc.是一家临床阶段的制药公司，开发药物成瘾的非成瘾性治疗方法，包括于2011年12月至2017年7月担任首席运营官和首席财务官，并于2014年9月至2017年7月担任总裁，并于2017年7月至2018年4月担任顾问。在其职业生涯早期，Weis先生于2010年8月至2011年11月担任ENSA Holdings，LLC的首席财务官，该公司专注于环境可持续农业技术和水稻生产技术。从2006年到2010年，他担任NovaVision，Inc.（一家治疗和诊断视力恢复公司）的副总裁和秘书兼财务主管。在此之前，他于2000年至2005年担任GMP Companies，Inc.的首席财务官兼财务主管，该公司开发和商业化制药、医疗设备和诊断技术。Weis先生于1986年至2000年担任跨国专业服务公司Ernst & Young的高级经理。Weis先生与他人合着了多篇科学论文和演讲，并且是多项专利和专利申请的发明人。Weis先生还在Jupiter Neurosciences，Inc.的董事会任职。Weis先生获得了佐治亚大学的会计工商管理学士学位，并且是一名注册会计师。
Holger Weis is has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Since December 2020, he has served as a Director, member of Audit and Compensation Committees as Alaunos Therapeutics, Inc. and was appointed CEO in July 2025. He is the principal of is Advisors, Inc., a company that provides consulting services to life science companies, since founding the company in April 2018. Beten December 2011 and April 2018, Mr. is served many roles at DemeRx, Inc. including COO, CFO, President as ll as a Consultant. From Augt 2010 to November 2011 Mr. is served as CFO for EnSA Holdings, LLC. Prior to his time at EnSA Holdings, LLC. Mr. is served as Vice President & CFO, Secretary and Treasurer at NovaVision, Inc. from January 2006 to Augt 2010. Prior to that, he served as the Chief Financial Officer & Treasurer of GMP Companies, Inc., a company that develops and commercializes pharmaceutical, medical device and diagnostic technologies, from 2000 to 2005. Earlier in his career, Mr. is served as a Senior Manager at Ernst & Young, a multinational professional services company, from 1986 to 2000. Mr. is received a Bachelor of Biness Administration in Accounting from the University of Georgia in 1985 and is a Certified Public Accountant. - Holger Weis自2020年12月以来一直担任我们的董事会成员。自2018年4月成立以来，Weis先生继续担任Weis Advisors，Inc.的负责人，该公司为生命科学公司提供咨询服务。在此之前，他曾在DemeRx，Inc.担任过多个职务，DemeRx，Inc.是一家临床阶段的制药公司，开发药物成瘾的非成瘾性治疗方法，包括于2011年12月至2017年7月担任首席运营官和首席财务官，并于2014年9月至2017年7月担任总裁，并于2017年7月至2018年4月担任顾问。在其职业生涯早期，Weis先生于2010年8月至2011年11月担任ENSA Holdings，LLC的首席财务官，该公司专注于环境可持续农业技术和水稻生产技术。从2006年到2010年，他担任NovaVision，Inc.（一家治疗和诊断视力恢复公司）的副总裁和秘书兼财务主管。在此之前，他于2000年至2005年担任GMP Companies，Inc.的首席财务官兼财务主管，该公司开发和商业化制药、医疗设备和诊断技术。Weis先生于1986年至2000年担任跨国专业服务公司Ernst & Young的高级经理。Weis先生与他人合着了多篇科学论文和演讲，并且是多项专利和专利申请的发明人。Weis先生还在Jupiter Neurosciences，Inc.的董事会任职。Weis先生获得了佐治亚大学的会计工商管理学士学位，并且是一名注册会计师。
- Holger Weis is has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Since December 2020, he has served as a Director, member of Audit and Compensation Committees as Alaunos Therapeutics, Inc. and was appointed CEO in July 2025. He is the principal of is Advisors, Inc., a company that provides consulting services to life science companies, since founding the company in April 2018. Beten December 2011 and April 2018, Mr. is served many roles at DemeRx, Inc. including COO, CFO, President as ll as a Consultant. From Augt 2010 to November 2011 Mr. is served as CFO for EnSA Holdings, LLC. Prior to his time at EnSA Holdings, LLC. Mr. is served as Vice President & CFO, Secretary and Treasurer at NovaVision, Inc. from January 2006 to Augt 2010. Prior to that, he served as the Chief Financial Officer & Treasurer of GMP Companies, Inc., a company that develops and commercializes pharmaceutical, medical device and diagnostic technologies, from 2000 to 2005. Earlier in his career, Mr. is served as a Senior Manager at Ernst & Young, a multinational professional services company, from 1986 to 2000. Mr. is received a Bachelor of Biness Administration in Accounting from the University of Georgia in 1985 and is a Certified Public Accountant.
- Michael A. Jerman
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Ferdinand Groenewald
Ferdinand Groenewald自2018年9月起担任MuscleMaker，Inc.首席财务官。Groenewald先生此前曾于2018年1月25日至2018年5月29日担任公司，肌肉制造商发展有限公司和肌肉制造商有限公司的财务Vice President，首席财务官和首席会计官。此外，Groenewald先生于2017年10月至2018年5月29日担任我们的财务总监。Groenewald先生是一名注册会计师，在财务和会计方面有着丰富的经验。从2017年2月至2017年10月，Groenewald先生担任Pharos Advisors，Inc.的高级财务会计顾问，服务于广泛的行业。2013年11月至2017年2月，他曾担任Financial Consulting Strategies，LLC的高级职员会计师，在那里他为各个行业提供广泛的会计，财务报告和审计前服务。2015年8月至2015年12月，Groenewald先生担任Valley National Bank的财务报告分析师。Groenewald先生持有南非大学（University of South Africa）会计学理学学士学位。
Ferdinand Groenewald has served in several capacities at the CFO Squad which provides outsced accounting and consulting services. From January 2, 2022 to July 31, 2022, Mr. Groenewald had served as the Chief Accounting Officer of Mcle Maker, Inc., a Nasdaq listed company. From September 2018 to January 2, 2022, Mr. Groenewald served as the Chief Financial Officer of Mcle Maker, Inc. From January 25, 2018 through May 29, 2018, Mr. Groenewald served as the Vice President of Finance, Principal Financial Officer and Principal Accounting Officer of Mcle Maker, Inc., Mcle Maker Development, LLC and Mcle Maker Corp., LLC. In addition, from October 2017 through May 29, 2018, he served as the controller of Mcle Maker, Inc. Mr. Groenewald is a certified public accountant with significant experience in finance and accounting. From July 2018 through Augt 2018, he served as senior financial reporting accountant of Wrinkle Gardner & Company, a full service tax, accounting and biness consulting firm. From February 2017 to October 2017, Mr. Groenewald served as Senior Financial Accounting Consultant at Pharos Advisors, Inc. serving a broad range of indtries. From November 2013 to February 2017, he served as a Senior Staff Accountant at Financial Consulting Strategies, LLC where he provided a broad range of accounting, financial reporting, and pre auditing services to vario indtries. From Augt 2015 to December 2015, Mr. Groenewald served as a Financial Reporting Analyst at Valley National Bank. Mr. Groenewald holds a Bachelor of Science in accounting from the University of South Africa. Mr. Groenewald is a Certified Public Account. Mr. Groenewald serves as a member of the Board of Directors of HeartCore Enterprises, Inc., a publicly reporting company that is listed on the Nasdaq Capital Market, since January 24, 2022. Mr. Groenewald also serves as a member of the Board of Directors of SYLA Technologies Co., Ltd., a publicly reporting company that is listed on the Nasdaq Capital Market, since December 1, 2022.- Ferdinand Groenewald自2018年9月起担任MuscleMaker，Inc.首席财务官。Groenewald先生此前曾于2018年1月25日至2018年5月29日担任公司，肌肉制造商发展有限公司和肌肉制造商有限公司的财务Vice President，首席财务官和首席会计官。此外，Groenewald先生于2017年10月至2018年5月29日担任我们的财务总监。Groenewald先生是一名注册会计师，在财务和会计方面有着丰富的经验。从2017年2月至2017年10月，Groenewald先生担任Pharos Advisors，Inc.的高级财务会计顾问，服务于广泛的行业。2013年11月至2017年2月，他曾担任Financial Consulting Strategies，LLC的高级职员会计师，在那里他为各个行业提供广泛的会计，财务报告和审计前服务。2015年8月至2015年12月，Groenewald先生担任Valley National Bank的财务报告分析师。Groenewald先生持有南非大学（University of South Africa）会计学理学学士学位。
- Ferdinand Groenewald has served in several capacities at the CFO Squad which provides outsced accounting and consulting services. From January 2, 2022 to July 31, 2022, Mr. Groenewald had served as the Chief Accounting Officer of Mcle Maker, Inc., a Nasdaq listed company. From September 2018 to January 2, 2022, Mr. Groenewald served as the Chief Financial Officer of Mcle Maker, Inc. From January 25, 2018 through May 29, 2018, Mr. Groenewald served as the Vice President of Finance, Principal Financial Officer and Principal Accounting Officer of Mcle Maker, Inc., Mcle Maker Development, LLC and Mcle Maker Corp., LLC. In addition, from October 2017 through May 29, 2018, he served as the controller of Mcle Maker, Inc. Mr. Groenewald is a certified public accountant with significant experience in finance and accounting. From July 2018 through Augt 2018, he served as senior financial reporting accountant of Wrinkle Gardner & Company, a full service tax, accounting and biness consulting firm. From February 2017 to October 2017, Mr. Groenewald served as Senior Financial Accounting Consultant at Pharos Advisors, Inc. serving a broad range of indtries. From November 2013 to February 2017, he served as a Senior Staff Accountant at Financial Consulting Strategies, LLC where he provided a broad range of accounting, financial reporting, and pre auditing services to vario indtries. From Augt 2015 to December 2015, Mr. Groenewald served as a Financial Reporting Analyst at Valley National Bank. Mr. Groenewald holds a Bachelor of Science in accounting from the University of South Africa. Mr. Groenewald is a Certified Public Account. Mr. Groenewald serves as a member of the Board of Directors of HeartCore Enterprises, Inc., a publicly reporting company that is listed on the Nasdaq Capital Market, since January 24, 2022. Mr. Groenewald also serves as a member of the Board of Directors of SYLA Technologies Co., Ltd., a publicly reporting company that is listed on the Nasdaq Capital Market, since December 1, 2022.
- Holger Weis
Holger Weis自2020年12月以来一直担任我们的董事会成员。自2018年4月成立以来，Weis先生继续担任Weis Advisors，Inc.的负责人，该公司为生命科学公司提供咨询服务。在此之前，他曾在DemeRx，Inc.担任过多个职务，DemeRx，Inc.是一家临床阶段的制药公司，开发药物成瘾的非成瘾性治疗方法，包括于2011年12月至2017年7月担任首席运营官和首席财务官，并于2014年9月至2017年7月担任总裁，并于2017年7月至2018年4月担任顾问。在其职业生涯早期，Weis先生于2010年8月至2011年11月担任ENSA Holdings，LLC的首席财务官，该公司专注于环境可持续农业技术和水稻生产技术。从2006年到2010年，他担任NovaVision，Inc.（一家治疗和诊断视力恢复公司）的副总裁和秘书兼财务主管。在此之前，他于2000年至2005年担任GMP Companies，Inc.的首席财务官兼财务主管，该公司开发和商业化制药、医疗设备和诊断技术。Weis先生于1986年至2000年担任跨国专业服务公司Ernst & Young的高级经理。Weis先生与他人合着了多篇科学论文和演讲，并且是多项专利和专利申请的发明人。Weis先生还在Jupiter Neurosciences，Inc.的董事会任职。Weis先生获得了佐治亚大学的会计工商管理学士学位，并且是一名注册会计师。
Holger Weis is has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Since December 2020, he has served as a Director, member of Audit and Compensation Committees as Alaunos Therapeutics, Inc. and was appointed CEO in July 2025. He is the principal of is Advisors, Inc., a company that provides consulting services to life science companies, since founding the company in April 2018. Beten December 2011 and April 2018, Mr. is served many roles at DemeRx, Inc. including COO, CFO, President as ll as a Consultant. From Augt 2010 to November 2011 Mr. is served as CFO for EnSA Holdings, LLC. Prior to his time at EnSA Holdings, LLC. Mr. is served as Vice President & CFO, Secretary and Treasurer at NovaVision, Inc. from January 2006 to Augt 2010. Prior to that, he served as the Chief Financial Officer & Treasurer of GMP Companies, Inc., a company that develops and commercializes pharmaceutical, medical device and diagnostic technologies, from 2000 to 2005. Earlier in his career, Mr. is served as a Senior Manager at Ernst & Young, a multinational professional services company, from 1986 to 2000. Mr. is received a Bachelor of Biness Administration in Accounting from the University of Georgia in 1985 and is a Certified Public Accountant.- Holger Weis自2020年12月以来一直担任我们的董事会成员。自2018年4月成立以来，Weis先生继续担任Weis Advisors，Inc.的负责人，该公司为生命科学公司提供咨询服务。在此之前，他曾在DemeRx，Inc.担任过多个职务，DemeRx，Inc.是一家临床阶段的制药公司，开发药物成瘾的非成瘾性治疗方法，包括于2011年12月至2017年7月担任首席运营官和首席财务官，并于2014年9月至2017年7月担任总裁，并于2017年7月至2018年4月担任顾问。在其职业生涯早期，Weis先生于2010年8月至2011年11月担任ENSA Holdings，LLC的首席财务官，该公司专注于环境可持续农业技术和水稻生产技术。从2006年到2010年，他担任NovaVision，Inc.（一家治疗和诊断视力恢复公司）的副总裁和秘书兼财务主管。在此之前，他于2000年至2005年担任GMP Companies，Inc.的首席财务官兼财务主管，该公司开发和商业化制药、医疗设备和诊断技术。Weis先生于1986年至2000年担任跨国专业服务公司Ernst & Young的高级经理。Weis先生与他人合着了多篇科学论文和演讲，并且是多项专利和专利申请的发明人。Weis先生还在Jupiter Neurosciences，Inc.的董事会任职。Weis先生获得了佐治亚大学的会计工商管理学士学位，并且是一名注册会计师。
- Holger Weis is has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Since December 2020, he has served as a Director, member of Audit and Compensation Committees as Alaunos Therapeutics, Inc. and was appointed CEO in July 2025. He is the principal of is Advisors, Inc., a company that provides consulting services to life science companies, since founding the company in April 2018. Beten December 2011 and April 2018, Mr. is served many roles at DemeRx, Inc. including COO, CFO, President as ll as a Consultant. From Augt 2010 to November 2011 Mr. is served as CFO for EnSA Holdings, LLC. Prior to his time at EnSA Holdings, LLC. Mr. is served as Vice President & CFO, Secretary and Treasurer at NovaVision, Inc. from January 2006 to Augt 2010. Prior to that, he served as the Chief Financial Officer & Treasurer of GMP Companies, Inc., a company that develops and commercializes pharmaceutical, medical device and diagnostic technologies, from 2000 to 2005. Earlier in his career, Mr. is served as a Senior Manager at Ernst & Young, a multinational professional services company, from 1986 to 2000. Mr. is received a Bachelor of Biness Administration in Accounting from the University of Georgia in 1985 and is a Certified Public Accountant.